688314.SH
康拓医疗
SSE · Healthcare · Medical - Devices · CN
CNY 30.76
−5.03%Aug 27, 2026, 10:52 UTC
Kangtuo Medical proposed a cash dividend of 1.5 yuan per 10 shares (tax inclusive), totaling 12.2442 million yuan.
Source:Aug 27, 2026, 10:52 UTC
Kangtuo Medical announced its H1 2026 results: net profit attributable to shareholders was 41.39 million yuan, down 24.74% year-on-year.
Source:Aug 25, 2026, 09:13 UTC
Kangtuo Medical's controlled subsidiary Xi'an Meiyan Tianshi Biotechnology Co., Ltd. obtained a Class III medical device registration certificate from China's National Medical Products Administration for injectable cross-linked sodium hyaluronate gel, used for correcting moderate-to-severe neck wrinkles, valid until August 23, 2031.
Source: